Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous abatacept vs placebo in diffuse cutaneous systemic sclerosis (Phase II)
2014-005323-27Phase 2Completed
- Sponsor
- University of Michigan
- Start
- Sep 2015
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing Abatacept SC weekly with Placebo SC weekly (2 arms). Primary endpoint: Change in Modified Rodnan Skin Score at 12 months. Started Sep 2015; status: completed.
02
Drugs
abatacept
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2014-005323-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005323-27.